title: Next-Generation Regimens: The Future of Hepatitis C Virus Therapy.
abstract: The treatment of chronic hepatitis C virus (HCV) has undergone a period of rapid evolution. The era of combination direct antivirals has led to high rates of sustained viral response (SVR), limited toxicities, and more broad applicability across patient demographics. Even current therapies have their limitations, however, including genotype specificity and variable durations of treatment depending on the presence or absence of cirrhosis. Developing a fixed-duration pangenotypic regimen that can broadly treat all stages of fibrosis with equal rates of SVR in all patients, irrespective of treatment experience, is the goal of future therapies. This article reviews antivirals in development.
authors.affiliation: Division of Gastroenterology and Nutrition, Department of Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA. Electronic address: johnvizuete@gmail.com.
authors.forename: John
authors.initials: J
authors.lastname: Vizuete
authors.affiliation: Division of Gastroenterology and Nutrition, Department of Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA.
authors.forename: Hope
authors.initials: H
authors.lastname: Hubbard
authors.affiliation: Division of Gastroenterology and Nutrition, Department of Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA.
authors.forename: Eric
authors.initials: E
authors.lastname: Lawitz
mesh_terms: D000577:Amides; D000998:Antiviral Agents / Q000627:therapeutic use*; D001552:Benzazepines / Q000627:therapeutic use; D001572:Benzofurans / Q000627:therapeutic use; D002219:Carbamates / Q000627:therapeutic use; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D003521:Cyclopropanes; D055808:Drug Discovery; D004359:Drug Therapy, Combination; D005544:Forecasting; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006576:Heterocyclic Compounds, 4 or More Rings / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D007211:Indoles / Q000627:therapeutic use; D007546:Isoquinolines / Q000627:therapeutic use; D035683:MicroRNAs; D058990:Molecular Targeted Therapy; D019384:Nucleic Acid Synthesis Inhibitors / Q000627:therapeutic use*; D011480:Protease Inhibitors / Q000627:therapeutic use; D011759:Pyrrolidines; D011810:Quinoxalines / Q000627:therapeutic use; D012367:RNA, Viral / Q000096:biosynthesis; D000069474:Sofosbuvir / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D014633:Valine / Q000031:analogs & derivatives; D017361:Viral Nonstructural Proteins / Q000037:antagonists & inhibitors; D047029:Lactams, Macrocyclic; D012324:RNA-Dependent RNA Polymerase; D001562:Benzimidazoles; D001578:Benzopyrans
chemical_list: D000577:Amides; D000998:Antiviral Agents; D001552:Benzazepines; D001572:Benzofurans; D002219:Carbamates; D003521:Cyclopropanes; D006576:Heterocyclic Compounds, 4 or More Rings; D007093:Imidazoles; D007211:Indoles; D007546:Isoquinolines; D035683:MicroRNAs; D019384:Nucleic Acid Synthesis Inhibitors; D011480:Protease Inhibitors; D011759:Pyrrolidines; D011810:Quinoxalines; D012367:RNA, Viral; D000069474:Sofosbuvir; D013449:Sulfonamides; D014633:Valine; D017361:Viral Nonstructural Proteins; C587012:8-cyclohexyl-N-((dimethylamino)sulfonyl)-1,1a,2,12b-tetrahydro-11-methoxy-1a-((3-methyl-3,8-diazabicyclo(3.2.1)oct-8-yl)carbonyl)cycloprop(d)indolo(2,1-a)(2)benzazepine-5-carboxamide; C531907:MIRN122 microRNA, human; C578009:grazoprevir; D047029:Lactams, Macrocyclic; C000589335:elbasvir; C087036:NS-5 protein, hepatitis C virus; D012324:RNA-Dependent RNA Polymerase; C000604171:velpatasvir; D001562:Benzimidazoles; D001578:Benzopyrans; C549273:daclatasvir; C571889:asunaprevir
keywords: Direct-acting antivirals; Genotype 1; Hepatitis C; Resistance-associated variants; Second generation